Selection and characterization of DNA aptamers for therapeutic drugs: voriconazole and carbamazepine
| dc.contributor.author | Kamel, Amira | |
| dc.date.accessioned | 2026-08-27T13:04:07Z | |
| dc.date.issued | 2026-08-27 | |
| dc.date.submitted | 2026-08-17 | |
| dc.description.abstract | Therapeutic drug monitoring (TDM) is currently a time-consuming and repetitive process of monitoring a drug’s concentration in the blood to ensure an effective level is achieved and avoid potentially dangerous sub-therapeutic or toxic levels. To date, this process relies on centralized medical laboratories equipped with expensive instrumentation and highly trained personnel. Aptamers, used as target binding for biosensors, are proposed as a solution for fast and cheap point-of-care-testing of the drugs that require TDM. However, only a few aptamers are available in the literature for such drugs, and not all the reported aptamers are well characterized and validated. My thesis aims to fill in this gap by performing aptamer selection for carbamazepine and characterizing the binding of aptamers for voriconazole. In this thesis, I first used the capture-SELEX method to select new aptamers for the antiepileptic drug carbamazepine (CBZ) as explained in chapter 2. After 17 rounds of selection and deep sequencing of the final library pool, I collected the common motifs from the top 61 sequences and grouped them into a structurally related group. Then, three potential aptamer candidates were selected for further binding characterization using Thioflavin T fluorescence spectroscopy and isothermal titration calorimetry. Unfortunately, both deep sequencing results analysis and binding assays confirmed that capture-SELEX failed to enrich high-affinity aptamers specific to this target. CBZ seems to be one of the challenging small-molecule targets because of its non-planarity and the steric crowding around its only functional group. The DNA sequences could not form strong non-covalent bonds with CBZ under the used conditions and current capture-SELEX protocol employed in this work. In chapter 3, we used Thioflavin-T fluorescence spectroscopy to characterize some aptamers previously selected by our group for another challenging small-molecule target: the antifungal drug voriconazole. A new aptamer was identified called VO3 with a KD value of 26 μM, high selectivity against similarly structured small molecules, and good stability in different buffer conditions and complex matrices such as serum. In addition, we used this aptamer to probe the nanopolymers cyclodextrins and learn more about the different interactions of α- and β- cyclodextrins (CD) with VOZ. As expected α-CD did not interact with VOZ, but β-CD seemed to have a greater affinity for VOZ than its affinity with the aptamer VO3. We could not use another orthogonal binding assay methods such as isothermal titration calorimetry or circular dichroism because of constraints related to VOZ’s poor water solubility. Nevertheless, I believe VO3 is a good candidate for further validation and development assays. Finally, in chapter 4, the conclusion and some suggested future directions were included. Through this thesis, we explore some of the challenges and setbacks for developing aptasensors, specially for the purpose of point-of-care-testing for drug requiring TDM. Since all these drugs fall under the category of small-molecule targets, selecting specific high-affinity aptamers for most of them is still a challenge. Using more advanced SELEX methods, modified DNA sequences or a specially structured library motif can help facilitate selection for aptamers of challenging targets such as CBZ. Even after selecting the aptamers, rigorous characterization assays should be implemented to confirm and validate the binding affinity of the aptamer and its suitability for the final application. For VO3 for example, we recommend confirming its binding with further NMR or FRET assays before further development into electrochemical platforms. | |
| dc.identifier.uri | https://hdl.handle.net/10012/24080 | |
| dc.language.iso | en | |
| dc.pending | false | |
| dc.publisher | University of Waterloo | en |
| dc.subject | DNA | |
| dc.subject | antifungal | |
| dc.subject | anti-epileptic | |
| dc.subject | Thiofalvin T | |
| dc.subject | aptamer | |
| dc.subject | capture-SELEX | |
| dc.subject | characterization | |
| dc.subject | fluorescence spectroscopy | |
| dc.subject | cyclodextrin | |
| dc.subject | probing | |
| dc.subject | nano-polymer | |
| dc.subject | voriconazole | |
| dc.subject | carbamazepine | |
| dc.subject | therapeutic drug monitoring | |
| dc.subject | narrow therapeutic index drug | |
| dc.title | Selection and characterization of DNA aptamers for therapeutic drugs: voriconazole and carbamazepine | |
| dc.type | Master Thesis | |
| uws-etd.degree | Master of Science | |
| uws-etd.degree.department | Chemistry | |
| uws-etd.degree.discipline | Chemistry | |
| uws-etd.degree.grantor | University of Waterloo | en |
| uws-etd.embargo.terms | 0 | |
| uws.contributor.advisor | Liu, Juewen | |
| uws.contributor.affiliation1 | Faculty of Science | |
| uws.peerReviewStatus | Unreviewed | en |
| uws.published.city | Waterloo | en |
| uws.published.country | Canada | en |
| uws.published.province | Ontario | en |
| uws.scholarLevel | Graduate | en |
| uws.typeOfResource | Text | en |